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Preamble
The medical profession should play a central role in evalu-
ating the evidence related to drugs, devices, and procedures
for the detection, management, and prevention of disease.
When properly applied, expert analysis of available data on
the benefits and risks of these therapies and procedures can
improve the quality of care, optimize patient outcomes, and
favorably affect costs by focusing resources on the most
effective strategies. An organized and directed approach to a
thorough review of evidence has resulted in the production
of clinical practice guidelines that assist physicians in select-
ing the best management strategy for an individual patient.
Moreover, clinical practice guidelines can provide a foun-
dation for other applications, such as performance measures,
appropriate use criteria, and both quality improvement and
clinical decision support tools.
The American College of Cardiology Foundation
(ACCF) and the American Heart Association (AHA) have
jointly produced guidelines in the area of cardiovascular
disease since 1980. The ACCF/AHA Task Force on
Practice Guidelines (Task Force), charged with developing,
updating, and revising practice guidelines for cardiovascular
diseases and procedures, directs and oversees this effort.
Writing committees are charged with regularly reviewing
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patient-centric recommendations for clinical practice.
Experts in the subject under consideration are selected by
the ACCF and AHA to examine subject-specific data and
write guidelines in partnership with representatives from
other medical organizations and specialty groups. Writing
committees are asked to perform a formal literature review;
weigh the strength of evidence for or against particular tests,
treatments, or procedures; and include estimates of expected
outcomes where such data exist. Patient-specific modifiers,
comorbidities, and issues of patient preference that may
influence the choice of tests or therapies are considered.
When available, information from studies on cost is con-
sidered, but data on efficacy and outcomes constitute the
primary basis for the recommendations contained herein.
In analyzing the data and developing recommendations
and supporting text, the writing committee uses evidence-
based methodologies developed by the Task Force (1). The
lass of Recommendation (COR) is an estimate of the size
f the treatment effect considering risks versus benefits in
ddition to evidence and/or agreement that a given treat-
ent or procedure is or is not useful/effective or in some
ituations may cause harm. The Level of Evidence (LOE) is
n estimate of the certainty or precision of the treatment
ffect. The writing committee reviews and ranks evidence
upporting each recommendation with the weight of evi-
ence ranked as LOE A, B, or C according to specific
efinitions that are included in Table 1. Studies are identi-
ed as observational, retrospective, prospective, or random-
zed where appropriate. For certain conditions for which
nadequate data are available, recommendations are based
n expert consensus and clinical experience and are ranked
s LOE C. When recommendations at LOE C are sup-
orted by historical clinical data, appropriate references
including clinical reviews) are cited if available. For issues
or which sparse data are available, a survey of current
ractice among the clinicians on the writing committee is
he basis for LOE C recommendations, and no references
re cited. The schema for COR and LOE is summarized in
able 1, which also provides suggested phrases for writing
ecommendations within each COR. A new addition to this
ethodology is separation of the Class III recommenda-
ions to delineate if the recommendation is determined to be
f “no benefit” or is associated with “harm” to the patient. In
ddition, in view of the increasing number of comparative
ffectiveness studies, comparator verbs and suggested
hrases for writing recommendations for the comparative
ffectiveness of one treatment or strategy versus another
ave been added for COR I and IIa, LOE A or B only.
In view of the advances in medical therapy across the
pectrum of cardiovascular diseases, the Task Force has
esignated the term guideline–directed medical therapy
GDMT) to represent optimal medical therapy as defined by
CCF/AHA guideline–recommended therapies (primarily
lass I). This new term, GDMT, will be used herein andhroughout all future guidelines. tBecause the ACCF/AHA practice guidelines address
patient populations (and healthcare providers) residing in
North America, drugs that are not currently available in
North America are discussed in the text without a specific
COR. For studies performed in large numbers of subjects
outside North America, each writing committee reviews the
potential influence of different practice patterns and patient
populations on the treatment effect and relevance to the
ACCF/AHA target population to determine whether the
findings should inform a specific recommendation.
The ACCF/AHA practice guidelines are intended to
assist healthcare providers in clinical decision making by
describing a range of generally acceptable approaches to the
diagnosis, management, and prevention of specific diseases
or conditions. The guidelines attempt to define practices
that meet the needs of most patients in most circumstances.
The ultimate judgment regarding the care of a particular
patient must be made by the healthcare provider and patient
in light of all the circumstances presented by that patient.
As a result, situations may arise for which deviations from
these guidelines may be appropriate. Clinical decision mak-
ing should involve consideration of the quality and avail-
ability of expertise in the area where care is provided. When
these guidelines are used as the basis for regulatory or payer
decisions, the goal should be improvement in quality of care.
The Task Force recognizes that situations arise in which
additional data are needed to inform patient care more
effectively; these areas will be identified within each respec-
tive guideline when appropriate.
Prescribed courses of treatment in accordance with these
recommendations are effective only if followed. Because lack
of patient understanding and adherence may adversely affect
outcomes, physicians and other healthcare providers should
make every effort to engage the patient’s active participation
in prescribed medical regimens and lifestyles. In addition,
patients should be informed of the risks, benefits, and
alternatives to a particular treatment and be involved in
shared decision making whenever feasible, particularly for
COR IIa and IIb, where the benefit-to-risk ratio may be
lower.
The Task Force makes every effort to avoid actual,
potential, or perceived conflicts of interest that may arise as
a result of industry relationships or personal interests among
the members of the writing committee. All writing com-
mittee members and peer reviewers of the guideline are
required to disclose all such current relationships, as well as
those existing 12 months previously. In December 2009, the
ACCF and AHA implemented a new policy for relation-
ships with industry and other entities (RWI) that requires
the writing committee chair plus a minimum of 50% of the
writing committee to have no relevant RWI (Appendix 1 for
he ACCF/AHA definition of relevance). These statements
re reviewed by the Task Force and all members during each
onference call and meeting of the writing committee and
re updated as changes occur. All guideline recommenda-
ions require a confidential vote by the writing committee
TB only
2587JACC Vol. 58, No. 24, 2011 Hillis et al.
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bers. Members are not permitted to write, and must rescue
themselves from voting on, any recommendation or section
to which their RWI apply. Members who recused themselves
from voting are indicated in the list of writing committee
members, and section recusals are noted in Appendix 1.
Authors’ and peer reviewers’ RWI pertinent to this guideline
are disclosed in Appendixes 1 and 2, respectively. Additionally,
to ensure complete transparency, writing committee members’
comprehensive disclosure information—including RWI not
pertinent to this document—is available as an online supple-
ment. Comprehensive disclosure information for the Task
Force is also available online at www.cardiosource.org/ACC/
Table 1. Applying Classification of Recommendations and Leve
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak
Although randomized trials are unavailable, there may be a very clear clinical consensus that a
Data available from clinical trials or registries about the usefulness/efficacy in different subp
failure, and prior aspirin use.
†For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and
treatments or strategies being evaluated.About-ACC/Leadership/Guidelines-and-Documents-Task- lForces.aspx. The work of the writing committee was supported
exclusively by the ACCF and AHA without commercial
support. Writing committee members volunteered their time
for this activity.
In an effort to maintain relevance at the point of care for
practicing physicians, the Task Force continues to oversee
an ongoing process improvement initiative. As a result, in
response to pilot projects, evidence tables (with references
linked to abstracts in PubMed) have been added.
In April 2011, the Institute of Medicine released 2
reports: Finding What Works in Health Care: Standards for
Systematic Reviews and Clinical Practice Guidelines We Can
rust (2,3). It is noteworthy that the ACCF/AHA guide-
vidence
important clinical questions addressed in the guidelines do not lend themselves to clinical trials.
lar test or therapy is useful or effective.
ons, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart
), studies that support the use of comparator verbs should involve direct comparisons of thel of E
. Many
particu
opulatiines are cited as being compliant with many of the proposed
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current methodology is under way, with further enhance-
ments anticipated.
The recommendations in this guideline are considered
current until they are superseded by a focused update or the
full-text guideline is revised. Guidelines are official policy of
both the ACCF and AHA.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
1. Introduction
1.1. Methodology and Evidence Review
Whenever possible, the recommendations listed in this docu-
ment are evidence based. Articles reviewed in this guideline
revision covered evidence from the past 10 years through
January 2011, as well as selected other references through
April 2011. Searches were limited to studies, reviews, and
evidence conducted in human subjects that were published
in English. Key search words included but were not limited
to: analgesia, anastomotic techniques, antiplatelet agents, au-
tomated proximal clampless anastomosis device, asymptomatic
ischemia, Cardica C-port, cost effectiveness, depressed left ven-
tricular (LV) function, distal anastomotic techniques, direct
proximal anastomosis on aorta, distal anastomotic devices,
emergency coronary artery bypass graft (CABG) and ST-
elevation myocardial infarction (STEMI), heart failure, inter-
rupted sutures, LV systolic dysfunction, magnetic connectors,
PAS-Port automated proximal clampless anastomotic device,
patency, proximal connectors, renal disease, sequential anasto-
mosis, sternotomy, symmetry connector, symptomatic ischemia,
proximal connectors, sequential anastomosis, T grafts, thoracot-
omy, U-clips, Ventrica Magnetic Vascular Port system, Y grafts.
Additionally, the committee reviewed documents related to
the subject matter previously published by the ACCF and
AHA. References selected and published in this document
are representative but not all-inclusive.
The guideline is focused on the safe, appropriate, and
efficacious performance of CABG. The STEMI, percuta-
neous coronary intervention (PCI), and CABG guidelines
were written concurrently, with additional collaboration
from the Stable Ischemic Heart Disease (SIHD) guideline
writing committee. This allowed greater collaboration
among the different writing committees on topics such as
PCI in STEMI and revascularization strategies in patients
with coronary artery disease (CAD) (including unprotected
left main PCI, multivessel disease revascularization, and
hybrid procedures).
In accordance with the direction of the Task Force and
feedback from readers, in this iteration of the guideline, the
amount of text has been shortened, and emphasis has been
placed on summary statements rather than detailed discus-
sion of numerous individual trials. Online supplemental
evidence and summary tables have been created to docu-ment the studies and data considered for new or changed
guideline recommendations.
Because the executive summary contains only the recom-
mendations, the reader is encouraged to consult the full-text
guideline (4) for additional detail on the recommendations
and guidance on the care of the patient undergoing CABG.
1.2. Organization of the Writing Committee
The committee was composed of acknowledged experts in
CABG, interventional cardiology, general cardiology, and
cardiovascular anesthesiology. The committee included rep-
resentatives from the ACCF, AHA, American Association
for Thoracic Surgery, Society of Cardiovascular Anesthesi-
ologists, and Society of Thoracic Surgeons (STS).
1.3. Document Review and Approval
This document was reviewed by 2 official reviewers, each
nominated by both the ACCF and the AHA, as well as 1
reviewer each from the American Association for Thoracic
Surgery, Society of Cardiovascular Anesthesiologists, and
STS, as well as members from the ACCF/AHA Task Force
on Data Standards, ACCF/AHA Task Force on Perfor-
mance Measures, ACCF Surgeons’ Scientific Council,
ACCF Interventional Scientific Council, and Southern
Thoracic Surgical Association. All information on review-
ers’ RWIs was distributed to the writing committee and is
published in this document (Appendix 2). This document
was approved for publication by the governing bodies of the
ACCF and the AHA and endorsed by the American
Association for Thoracic Surgery, Society of Cardiovascular
Anesthesiologists, and STS.
2. Procedural Considerations:
Recommendations
2.1. Anesthetic Considerations
CLASS I
1. Anesthetic management directed toward early postoperative extu-
bation and accelerated recovery of low- to medium-risk patients
undergoing uncomplicated CABG is recommended (5–7). (Level of
Evidence: B)
2. Multidisciplinary efforts are indicated to ensure an optimal level of
analgesia and patient comfort throughout the perioperative period
(8–12). (Level of Evidence: B)
3. Efforts are recommended to improve interdisciplinary communica-
tion and patient safety in the perioperative environment (e.g.,
formalized checklist-guided multidisciplinary communication)
(13–16). (Level of Evidence: B)
4. A fellowship-trained cardiac anesthesiologist (or experienced board-
certified practitioner) credentialed in the use of perioperative trans-
esophageal echocardiography is recommended to provide or super-
vise anesthetic care of patients who are considered to be at high risk
(17–19). (Level of Evidence: C)
CLASS IIa
1. Volatile anesthestic-based regimens can be useful in facilitating
early extubation and reducing patient recall (6,20–22). (Level of
Evidence: A)
22
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1. The effectiveness of high thoracic epidural anesthesia/analgesia for
routine analgesic use is uncertain (23–26). (Level of Evidence: B)
CLASS III: HARM
1. Cyclooxygenase-2 inhibitors are not recommended for pain relief in
the postoperative period after CABG (27,28). (Level of Evidence: B)
2. Routine use of early extubation strategies in facilities with limited
backup for airway emergencies or advanced respiratory support is
potentially harmful. (Level of Evidence: C)
2.2. Bypass Graft Conduit
CLASS I
1. If possible, the left internal mammary artery (LIMA) should be used
to bypass the left anterior descending (LAD) artery when bypass of
the LAD artery is indicated (29–32). (Level of Evidence: B)
CLASS IIa
1. The right internal mammary artery is probably indicated to bypass
the LAD artery when the LIMA is unavailable or unsuitable as a
bypass conduit. (Level of Evidence: C)
. When anatomically and clinically suitable, use of a second internal
mammary artery to graft the left circumflex or right coronary artery
(when critically stenosed and perfusing LV myocardium) is reason-
able to improve the likelihood of survival and to decrease reinter-
vention (33–37). (Level of Evidence: B)
CLASS IIb
1. Complete arterial revascularization may be reasonable in patients
less than or equal to 60 years of age with few or no comorbidities.
(Level of Evidence: C)
2. Arterial grafting of the right coronary artery may be reasonable
when a critical (90%) stenosis is present (32,36,38). (Level of
Evidence: B)
3. Use of a radial artery graft may be reasonable when grafting
left-sided coronary arteries with severe stenoses (70%) and right-
sided arteries with critical stenoses (90%) that perfuse LV myo-
cardium (39–44). (Level of Evidence: B)
CLASS III: HARM
1. An arterial graft should not be used to bypass the right coronary
artery with less than a critical stenosis (90%) (32). (Level of
Evidence: C)
2.3. Intraoperative Transesophageal
Echocardiography
CLASS I
1. Intraoperative transesophageal echocardiography should be per-
formed for evaluation of acute, persistent, and life-threatening
hemodynamic disturbances that have not responded to treatment
(45,46). (Level of Evidence: B)
. Intraoperative transesophageal echocardiography should be per-
formed in patients undergoing concomitant valvular surgery
(45,47). (Level of Evidence: B)
CLASS IIa
1. Intraoperative transesophageal echocardiography is reasonable for
monitoring of hemodynamic status, ventricular function, regional
wall motion, and valvular function in patients undergoing CABG(46,48–53). (Level of Evidence: B)2.4. Preconditioning/Management of
Myocardial Ischemia
CLASS I
1. Management targeted at optimizing the determinants of coronary
arterial perfusion (e.g., heart rate, diastolic or mean arterial pres-
sure, and right ventricular or LV end-diastolic pressure) is recom-
mended to reduce the risk of perioperative myocardial ischemia
and infarction (54–58). (Level of Evidence: B)
CLASS IIa
1. Volatile-based anesthesia can be useful in reducing the risk of
perioperative myocardial ischemia and infarction (59–62). (Level of
Evidence: A)
CLASS IIb
1. The effectiveness of prophylactic pharmacological therapies or
controlled reperfusion strategies aimed at inducing preconditioning
or attenuating the adverse consequences of myocardial reperfusion
injury or surgically induced systemic inflammation is uncertain
(63–70). (Level of Evidence: A)
2. Mechanical preconditioning might be considered to reduce the risk
of perioperative myocardial ischemia and infarction in patients
undergoing off-pump CABG (71–73). (Level of Evidence: B)
3. Remote ischemic preconditioning strategies using peripheral-
extremity occlusion/reperfusion might be considered to attenuate
the adverse consequences of myocardial reperfusion injury (74–76).
(Level of Evidence: B)
4. The effectiveness of postconditioning strategies to attenuate the
adverse consequences of myocardial reperfusion injury is uncertain
(77,78). (Level of Evidence: C)
2.5. Clinical Subsets
2.5.1. CABG in Patients With
Acute Myocardial Infarction
CLASS I
1. Emergency CABG is recommended in patients with acute myocar-
dial infarction (MI) in whom 1) primary PCI has failed or cannot be
performed, 2) coronary anatomy is suitable for CABG, and 3) persistent
ischemia of a significant area of myocardium at rest and/or hemo-
dynamic instability refractory to nonsurgical therapy is present
(79–83). (Level of Evidence: B)
2. Emergency CABG is recommended in patients undergoing surgical
repair of a postinfarction mechanical complication of MI, such as
ventricular septal rupture, mitral valve insufficiency because of
papillary muscle infarction and/or rupture, or free wall rupture
(84–88). (Level of Evidence: B)
3. Emergency CABG is recommended in patients with cardiogenic
shock and who are suitable for CABG irrespective of the time
interval from MI to onset of shock and time from MI to CABG
(82,89–91). (Level of Evidence: B)
4. Emergency CABG is recommended in patients with life-threatening
ventricular arrhythmias (believed to be ischemic in origin) in the
presence of left main stenosis greater than or equal to 50% and/or
3-vessel CAD (92). (Level of Evidence: C)
CLASS IIa
1. The use of CABG is reasonable as a revascularization strategy in
patients with multivessel CAD with recurrent angina or MI within the
first 48 hours of STEMI presentation as an alternative to a more
delayed strategy (79,81,83,93). (Level of Evidence: B)
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patients greater than 75 years of age with ST-segment elevation or
left bundle branch block who are suitable for revascularization
irrespective of the time interval from MI to onset of shock (94–98).
(Level of Evidence: B)
CLASS III: HARM
1. Emergency CABG should not be performed in patients with persis-
tent angina and a small area of viable myocardium who are stable
hemodynamically. (Level of Evidence: C)
2. Emergency CABG should not be performed in patients with no-
reflow (successful epicardial reperfusion with unsuccessful micro-
vascular reperfusion). (Level of Evidence: C)
2.5.2. Life-Threatening Ventricular Arrhythmias
CLASS I
1. CABG is recommended in patients with resuscitated sudden cardiac
death or sustained ventricular tachycardia thought to be caused by
significant CAD (50% stenosis of left main coronary artery and/or
70% stenosis of 1, 2, or all 3 epicardial coronary arteries) and
resultant myocardial ischemia (92,99,100). (Level of Evidence: B)
CLASS III: HARM
1. CABG should not be performed in patients with ventricular tachy-
cardia with scar and no evidence of ischemia. (Level of Evidence: C)
2.5.3. Emergency CABG After Failed PCI
CLASS I
1. Emergency CABG is recommended after failed PCI in the presence
of ongoing ischemia or threatened occlusion with substantial myo-
cardium at risk (101,102). (Level of Evidence: B)
2. Emergency CABG is recommended after failed PCI for hemody-
namic compromise in patients without impairment of the coagula-
tion system and without a previous sternotomy (101,103,104).
(Level of Evidence: B)
CLASS IIa
1. Emergency CABG is reasonable after failed PCI for retrieval of a
foreign body (most likely a fractured guidewire or stent) in a crucial
anatomic location. (Level of Evidence: C)
. Emergency CABG can be beneficial after failed PCI for hemody-
namic compromise in patients with impairment of the coagulation
system and without previous sternotomy. (Level of Evidence: C)
CLASS IIb
1. Emergency CABG might be considered after failed PCI for hemody-
namic compromise in patients with previous sternotomy. (Level of
Evidence: C)
CLASS III: HARM
1. Emergency CABG should not be performed after failed PCI in the
absence of ischemia or threatened occlusion. (Level of Evidence: C)
. Emergency CABG should not be performed after failed PCI if revas-
cularization is impossible because of target anatomy or a no-reflow
state. (Level of Evidence: C)
2.5.4. CABG in Association With Other
Cardiac Procedures
CLASS I
1. CABG is recommended in patients undergoing noncoronary cardiac
surgery with greater than or equal to 50% luminal diameter narrow-
ing of the left main coronary artery or greater than or equal to 70%luminal diameter narrowing of other major coronary arteries. (Level
of Evidence: C)
CLASS IIa
1. The use of the LIMA is reasonable to bypass a significantly narrowed
LAD artery in patients undergoing noncoronary cardiac surgery.
(Level of Evidence: C)
2. CABG of moderately diseased coronary arteries (50% luminal
diameter narrowing) is reasonable in patients undergoing noncoro-
nary cardiac surgery. (Level of Evidence: C)
3. CAD Revascularization:
Recommendations
Recommendations and text in this section are the result of
extensive collaborative discussions between the PCI and
CABG writing committees as well as key members of the
SIHD and Unstable Angina/Non–ST-Elevation Myocar-
dial Infarction (UA/NSTEMI) writing committees. Cer-
tain issues, such as older versus more contemporary studies,
primary analyses versus subgroup analyses, and prospective
versus post hoc analyses, have been carefully weighed in
designating COR and LOE; they are addressed in the
appropriate corresponding text (4).
The goals of revascularization for patients with CAD are
to 1) to improve survival and 2) to relieve symptoms. The
following text contains recommendations for revasculariza-
tion to improve survival and symptoms. These recommen-
dations are summarized in Tables 2 and 3.
Revascularization recommendations in this section are
predominantly based on studies of patients with symptom-
atic SIHD and should be interpreted in this context. As
discussed later in this section, recommendations on the type
of revascularization are, in general, applicable to patients
with UA/NSTEMI. In some cases (e.g., unprotected left
main CAD), specific recommendations are made for pa-
tients with UA/NSTEMI or STEMI.
3.1. Heart Team Approach to
Revascularization Decisions
CLASS I
1. A Heart Team approach to revascularization is recommended in
patients with unprotected left main or complex CAD (105–107).
(Level of Evidence: C)
CLASS IIa
1. Calculation of the STS and SYNTAX (Synergy between Percutaneous
Coronary Intervention with TAXUS and Cardiac Surgery) scores is
reasonable in patients with unprotected left main and complex CAD
(107–114). (Level of Evidence: B)
3.2. Revascularization to Improve Survival
Left Main CAD Revascularization
CLASS I
1. CABG to improve survival is recommended for patients with signif-
icant (50% diameter stenosis) left main coronary artery stenosis
(115–121). (Level of Evidence: B)
d
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Anatomic
Setting COR LOE References
UPLM or complex CAD
CABG and PCI I—Heart Team approach recommended C (105–107)
CABG and PCI IIa—Calculation of the STS and SYNTAX scores B (107–114)
UPLM*
CABG I B (115–121)
PCI IIa—For SIHD when both of the following are present:
● Anatomic conditions associated with a low risk of PCI procedural complications
and a high likelihood of good long-term outcome
(e.g., a low SYNTAX score of 22, ostial or trunk left main CAD)
● Clinical characteristics that predict a significantly increased risk of
adverse surgical outcomes (e.g., STS-predicted risk of operative mortality 5%)
B (108,110,111,122–140,168)
IIa—For UA/NSTEMI if not a CABG candidate B (111,127,129–131,136,137,139,140,142)
IIa—For STEMI when distal coronary flow is TIMI flow grade 3 and PCI can be
performed more rapidly and safely than CABG
C (124,143,144)
IIb—For SIHD when both of the following are present:
● Anatomic conditions associated with a low to intermediate risk of PCI procedural
complications and intermediate to high likelihood of good long-term outcome
(e.g., low–intermediate SYNTAX score of 33, bifurcation left main CAD)
● Clinical characteristics that predict an increased risk of adverse surgical
outcomes (e.g., moderate–severe COPD, disability from prior stroke, or
prior cardiac surgery; STS-predicted risk of operative mortality 2%)
B (108,110,111,122–137,139,145)
III: Harm—For SIHD in patients (versus performing CABG) with unfavorable anatomy
and for PCI and who are good candidates for CABG
B (108,110,111,115–123)
3-vessel disease with or without proximal LAD artery disease*
CABG I B (117,121,146–149)
IIa—It is reasonable to choose CABG over PCI in patients with complex 3-vessel
CAD (e.g., SYNTAX 22) who are good candidates for CABG
B (123,138,148,164–165)
PCI IIb—Of uncertain benefit B (117,146,148,176)
2-vessel disease with proximal LAD artery disease*
CABG I B (117,121,146–149)
PCI IIb—Of uncertain benefit B (117,146,148,176)
2-vessel disease without proximal LAD artery disease*
CABG IIa—With extensive ischemia B (153–156)
IIb—Of uncertain benefit without extensive ischemia C (148)
PCI IIb—Of uncertain benefit B (117,146,148,176)
1-vessel proximal LAD artery disease
CABG IIa—With LIMA for long-term benefit B (30,31,121,148)
PCI IIb—of uncertain benefit B (117,146,148,176)
1-vessel disease without proximal LAD artery involvement
CABG III: Harm B (121,146,153,154,188–192)
PCI III: Harm B (121,146,153,154,188–192)
LV dysfunction
CABG IIa—EF 35% to 50% B (121,157–161)
CABG IIb—EF 35% without significant left main CAD B (121, 157–161,177,178)
PCI Insufficient data
Survivors of sudden cardiac death with presumed ischemia-mediated VT
CABG I B (99,150,152)
PCI I C (150)
No anatomic or physiological criteria for revascularization
CABG III: Harm B (121,146,153,154,188–192)
PCI III: Harm B (121,146,153,154,188–192)
*In patients with multivessel disease who also have diabetes, it is reasonable to choose CABG (with LIMA) over PCI (155,168–175) (Class IIa/LOE: B).
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; COR, class of recommendation; EF, ejection fraction; LAD, left anterior
escending; LIMA, left internal mammary artery; LOE, level of evidence; LV, left ventricular; N/A, not applicable; PCI, percutaneous coronary intervention; SIHD, stable ischemic heart disease; STEMI,
T-elevation myocardial infarction; STS, Society of Thoracic Surgeons; SYNTAX, Synergy between percutaneous coronary intervention with TAXUS and cardiac surgery; TIMI, Thrombolysis In Myocardial
nfarction; UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction; UPLM, unprotected left main; and VT, ventricular tachycardia.
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1. PCI to improve survival is reasonable as an alternative to CABG in
selected stable patients with significant (50% diameter stenosis)
unprotected left main CAD with: 1) anatomic conditions associated
with a low risk of PCI procedural complications and a high likelihood of
good long-term outcome (e.g., a low SYNTAX score [22], ostial or
trunk left main CAD); and 2) clinical characteristics that predict a
significantly increased risk of adverse surgical outcomes (e.g., STS-
predicted risk of operative mortality 5%) (108,110,111,122–
140,168). (Level of Evidence: B)
. PCI to improve survival is reasonable in patients with UA/NSTEMI
when an unprotected left main coronary artery is the culprit lesion
and the patient is not a candidate for CABG (111,127,129–
131,136,137,139,140,142). (Level of Evidence: B)
. PCI to improve survival is reasonable in patients with acute STEMI
when an unprotected left main coronary artery is the culprit lesion,
distal coronary flow is less than Thrombolysis In Myocardial Infarc-
tion grade 3, and PCI can be performedmore rapidly and safely than
CABG (124,143,144). (Level of Evidence: C)
CLASS IIb
1. PCI to improve survival may be reasonable as an alternative to
CABG in selected stable patients with significant (50% diameter
stenosis) unprotected left main CAD with: 1) anatomic conditions
associated with a low to intermediate risk of PCI procedural
complications and an intermediate to high likelihood of good
long-term outcome (e.g., low–intermediate SYNTAX score of
33, bifurcation left main CAD); and 2) clinical characteristics
that predict an increased risk of adverse surgical outcomes (e.g.,
moderate–severe chronic obstructive pulmonary disease, disabil-
ity from previous stroke, or previous cardiac surgery; STS-
predicted risk of operative mortality 2%) (108,110,111,122–
140,145). (Level of Evidence: B)
CLASS III: HARM
1. PCI to improve survival should not be performed in stable pa-
tients with significant (50% diameter stenosis) unprotected left
main CAD who have unfavorable anatomy for PCI and who are
good candidates for CABG (108,110,111,115–123). (Level of
Table 3. Revascularization to Improve Symptoms With Signific
r Physiological (FFR<0.80) Coronary Artery Stenoses
Clinical Setting
1 significant stenoses amenable to revascularization and unacceptable an
despite GDMT
1 significant stenoses and unacceptable angina in whom GDMT cannot be
implemented because of medication contraindications, adverse effects, o
patient preferences
Previous CABG with 1 significant stenoses associated with ischemia and
unacceptable angina despite GDMT
Complex 3-vessel CAD (e.g., SYNTAX score 22) with or without involvemen
proximal LAD artery and a good candidate for CABG
Viable ischemic myocardium that is perfused by coronary arteries that are n
amenable to grafting
No anatomic or physiologic criteria for revascularization
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COR, class of recommen
not applicable; PCI, percutaneous coronary intervention; SYNTAX, Synergy between Percutaneous CEvidence: B)Non–Left Main CAD Revascularization
CLASS I
1. CABG to improve survival is beneficial in patients with significant
(70% diameter) stenoses in 3 major coronary arteries (with or
without involvement of the proximal LAD artery) or in the proximal
LAD plus 1 other major coronary artery (117,121,146–149). (Level
of Evidence: B)
. CABG or PCI to improve survival is beneficial in survivors of sudden
cardiac death with presumed ischemia-mediated ventricular
tachycardia caused by significant (70% diameter) stenosis in a
major coronary artery. (CABG Level of Evidence: B [99,150,152];
PCI Level of Evidence: C [150])
CLASS IIa
1. CABG to improve survival is reasonable in patients with significant
(70% diameter) stenoses in 2 major coronary arteries with severe
or extensive myocardial ischemia (e.g., high-risk criteria on stress
testing, abnormal intracoronary hemodynamic evaluation, or20%
perfusion defect by myocardial perfusion stress imaging) or target
vessels supplying a large area of viable myocardium (153–156).
(Level of Evidence: B)
2. CABG to improve survival is reasonable in patients with mild–
moderate LV systolic dysfunction (ejection fraction 35% to 50%)
and significant (70% diameter stenosis) multivessel CAD or prox-
imal LAD coronary artery stenosis, when viable myocardium is
present in the region of intended revascularization (121,157–161).
(Level of Evidence: B)
3. CABG with a LIMA graft to improve survival is reasonable in patients
with significant (70% diameter) stenosis in the proximal LAD
artery and evidence of extensive ischemia (30,31,121,148). (Level
of Evidence: B)
4. It is reasonable to choose CABG over PCI to improve survival in patients
with complex 3-vessel CAD (e.g., SYNTAX score 22), with or without
involvement of the proximal LAD artery, who are good candidates for
CABG (123,138,148,164–165). (Level of Evidence: B)
. CABG is probably recommended in preference to PCI to improve
survival in patients with multivessel CAD and diabetes mellitus,
particularly if a LIMA graft can be anastomosed to the LAD artery
natomic (>50% Left Main or >70% Non–Left Main CAD)
COR LOE References
ICABG
IPCI
A (176,193–202)
IIaCABG
IIaPCI
C N/A
IIaPCI C (180,183,186)
IIbCABG C (187)
e IIaCABG preferred
over PCI
B (123,138,148,164–165)
IIbTMR as an
adjunct to CABG
B (203–207)
III: HarmCABG
III: HarmPCI
C N/A
FFR, fractional flow reserve; GDMT, guideline-directed medical therapy; LOE, level of evidence; N/A,
Intervention with TAXUS and Cardiac Surgery; and TMR, transmyocardial laser revascularization.ant A
gina
r
t of th
ot(155,168–175). (Level of Evidence: B)
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1. The usefulness of CABG to improve survival is uncertain in patients
with significant (70%) stenoses in 2 major coronary arteries not
involving the proximal LAD artery and without extensive ischemia
(148). (Level of Evidence: C)
2. The usefulness of PCI to improve survival is uncertain in patientswith 2- or
3-vessel CAD (with or without involvement of the proximal LAD artery) or
1-vessel proximal LAD disease (117,146,148,176). (Level of Evidence: B)
3. CABG might be considered with the primary or sole intent of
improving survival in patients with SIHD with severe LV systolic
dysfunction (ejection fraction35%) whether or not viable myocar-
dium is present (121,157–161,177,178). (Level of Evidence: B)
4. The usefulness of CABG or PCI to improve survival is uncertain in
patients with previous CABG and extensive anterior wall ischemia
on noninvasive testing (179–187). (Level of Evidence: B)
CLASS III: HARM
1. CABG or PCI should not be performed with the primary or sole intent
to improve survival in patients with SIHD with 1 or more coronary
stenoses that are not anatomically or functionally significant (e.g.,
70% diameter non–left main coronary artery stenosis, fractional
flow reserve 0.80, no or only mild ischemia on noninvasive
testing), involve only the left circumflex or right coronary artery, or
subtend only a small area of viable myocardium (121,146,
153,154,188–192). (Level of Evidence: B)
3.3. Revascularization to Improve Symptoms
CLASS I
1. CABG or PCI to improve symptoms is beneficial in patients with 1 or
more significant (70% diameter) coronary artery stenoses ame-
nable to revascularization and unacceptable angina despite GDMT
(176,193–202). (Level of Evidence: A)
CLASS IIa
1. CABG or PCI to improve symptoms is reasonable in patients with 1
or more significant (70% diameter) coronary artery stenoses and
unacceptable angina for whom GDMT cannot be implemented
because of medication contraindications, adverse effects, or patient
preferences. (Level of Evidence: C)
2. PCI to improve symptoms is reasonable in patients with previous
CABG, 1 or more significant (70% diameter) coronary artery
stenoses associated with ischemia, and unacceptable angina de-
spite GDMT (180,183,186). (Level of Evidence: C)
. It is reasonable to choose CABG over PCI to improve symptoms in
patients with complex 3-vessel CAD (e.g., SYNTAX score22), with or
without involvement of the proximal LAD artery, who are good candi-
dates for CABG (123,138,148,164,165). (Level of Evidence: B)
CLASS IIb
1. CABG to improve symptoms might be reasonable for patients with
previous CABG, 1 or more significant (70% diameter) coronary
artery stenoses not amenable to PCI, and unacceptable angina
despite GDMT (187). (Level of Evidence: C)
. Transmyocardial laser revascularization performed as an adjunct to
CABG to improve symptoms may be reasonable in patients with
viable ischemicmyocardium that is perfused by arteries that are not
amenable to grafting (203–207). (Level of Evidence: B)
CLASS III: HARM
1. CABG or PCI to improve symptoms should not be performed in
patients who do not meet anatomic (50% left main or 70%
non–left main stenosis) or physiological (e.g., abnormal fractional
flow reserve) criteria for revascularization. (Level of Evidence: C)3.4. Clinical Factors That May Influence the Choice
of Revascularization
3.4.1. Dual Antiplatelet Therapy Compliance and
Stent Thrombosis
CLASS III: HARM
1. PCI with coronary stenting (bare-metal stent or drug-eluting stent)
should not be performed if the patient is not likely to be able to
tolerate and comply with dual antiplatelet therapy for the appropri-
ate duration of treatment based on the type of stent implanted
(208–211). (Level of Evidence: B)
3.5. Hybrid Coronary Revascularization
CLASS IIa
1. Hybrid coronary revascularization (defined as the planned combina-
tion of LIMA-to-LAD artery grafting and PCI of1 non-LAD coronary
arteries) is reasonable in patients with 1 or more of the following
(212–220) (Level of Evidence: B):
a. Limitations to traditional CABG, such as heavily calcified proxi-
mal aorta or poor target vessels for CABG (but amenable to PCI);
b. Lack of suitable graft conduits;
c. Unfavorable LAD artery for PCI (i.e., excessive vessel tortuosity or
chronic total occlusion).
CLASS IIb
1. Hybrid coronary revascularization (defined as the planned combina-
tion of LIMA-to-LAD artery grafting and PCI of1 non-LAD coronary
arteries) may be reasonable as an alternative to multivessel PCI or
CABG in an attempt to improve the overall risk–benefit ratio of the
procedures. (Level of Evidence: C)
4. Perioperative Management:
Recommendations
4.1. Preoperative Antiplatelet Therapy
CLASS I
1. Aspirin (100 mg to 325 mg daily) should be administered to CABG
patients preoperatively (221–223). (Level of Evidence: B)
2. In patients referred for elective CABG, clopidogrel and ticagrelor
should be discontinued for at least 5 days before surgery (224–226)
(Level of Evidence: B) and prasugrel for at least 7 days (Level of
Evidence: C) to limit blood transfusions.
3. In patients referred for urgent CABG, clopidogrel and ticagrelor
should be discontinued for at least 24 hours to reduce major
bleeding complications (225,227–229). (Level of Evidence: B)
4. In patients referred for CABG, short-acting intravenous glycoprotein
IIb/IIIa inhibitors (eptifibatide or tirofiban) should be discontinued
for at least 2 to 4 hours before surgery (230,231) and abciximab for
at least 12 hours beforehand (232) to limit blood loss and transfu-
sions. (Level of Evidence: B)
CLASS IIb
1. In patients referred for urgent CABG, it may be reasonable to
perform surgery less than 5 days after clopidogrel or ticagrelor has
been discontinued and less than 7 days after prasugrel has been
discontinued. (Level of Evidence: C)
4.2. Postoperative Antiplatelet Therapy
CLASS I
1. If aspirin (100 mg to 325 mg daily) was not initiated preoperatively,it should be initiated within 6 hours postoperatively and then
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graft closure and adverse cardiovascular events (223,233,234).
(Level of Evidence: A)
CLASS IIa
1. For patients undergoing coronary artery bypass grafting, clopidogrel
75 mg daily is a reasonable alternative in patients who are intoler-
ant of or allergic to aspirin. (Level of Evidence: C)
4.3. Management of Hyperlipidemia
CLASS I
1. All patients undergoing CABG should receive statin therapy, unless
contraindicated (235–247,247a). (Level of Evidence: A)
2. In patients undergoing CABG, an adequate dose of statin should be
used to reduce low-density lipoprotein cholesterol to less than 100
mg/dL and to achieve at least a 30% lowering of low-density
lipoprotein cholesterol (235–239,247a). (Level of Evidence: C)
CLASS IIa
1. In patients undergoing CABG, it is reasonable to treat with statin
therapy to lower the low-density lipoprotein cholesterol to less than
70 mg/dL in very high-risk* patients (236–238,247a,248–250).
(Level of Evidence: C)
2. For patients undergoing urgent or emergency CABG who are not
taking a statin, it is reasonable to initiate high-dose statin therapy
immediately (250a). (Level of Evidence: C)
CLASS III: HARM
1. Discontinuation of statin or other dyslipidemic therapy is not recom-
mended before or after CABG in patients without adverse reactions
to therapy (251–253). (Level of Evidence: B)
4.4. Hormonal Manipulation
CLASS I
1. Use of continuous intravenous insulin to achieve and maintain an
early postoperative blood glucose concentration less than or equal
to 180 mg/dL while avoiding hypoglycemia is indicated to reduce
the incidence of adverse events, including deep sternal wound
infection, after CABG (254–256). (Level of Evidence: B)
CLASS IIb
1. The use of continuous intravenous insulin designed to achieve a
target intraoperative blood glucose concentration less than
140 mg/dL has uncertain effectiveness (257–259). (Level of
Evidence: B)
CLASS III: HARM
1. Postmenopausal hormonal therapy (estrogen/prosgesterone) should not
be administered to women undergoing CABG (260–262). (Level of Evi-
dence: B)
4.5. Perioperative Beta Blockers
CLASS I
1. Beta blockers should be administered for at least 24 hours before
CABG to all patients without contraindications to reduce the incidence
or clinical sequelae of postoperative AF (263–267,267a–267c). (Level
of Evidence: B)
*Presence of established cardiovascular disease plus 1) multiple major risk factors
(especially diabetes), 2) severe and poorly controlled risk factors (especially continued
cigarette smoking), 3) multiple risk factors of the metabolic syndrome (especially high
triglycerides 200 mg/dL plus non–high-density lipoprotein cholesterol 130
mg/dL with low high-density lipoprotein cholesterol [40 mg/dL]), and 4) acute
coronary syndromes.. Beta blockers should be reinstituted as soon as possible after CABG in
all patients without contraindications to reduce the incidence or clinical
sequelae of AF (263–267,267a–267c). (Level of Evidence: B)
. Beta blockers should be prescribed to all CABG patients without
contraindications at the time of hospital discharge. (Level of Evi-
dence: C)
CLASS IIa
1. Preoperative use of beta blockers in patients without contraindica-
tions, particularly in those with an LV ejection fraction (LVEF) greater
than 30%, can be effective in reducing the risk of in-hospital
mortality (268–270). (Level of Evidence: B)
. Beta blockers can be effective in reducing the incidence of periop-
erative myocardial ischemia (271–274). (Level of Evidence: B)
. Intravenous administration of beta blockers in clinically stable
patients unable to take oral medications is reasonable in the early
postoperative period (275). (Level of Evidence: B)
CLASS IIb
1. The effectiveness of preoperative beta blockers in reducing in-
hospital mortality rate in patients with LVEF less than 30% is
uncertain (268,276). (Level of Evidence: B)
4.6. Angiotensin-Converting Enzyme Inhibitors
and Angiotensin-Receptor Blockers
CLASS I
1. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-
receptor blockers given before CABG should be reinstituted postoper-
atively once the patient is stable, unless contraindicated (277–279).
(Level of Evidence: B)
2. ACE inhibitors or angiotensin-receptor blockers should be initiated
postoperatively and continued indefinitely in CABG patients who
were not receiving them preoperatively, who are stable, and who
have an LVEF less than or equal to 40%, hypertension, diabetes
mellitus, or chronic kidney disease, unless contraindicated
(278,279a,279b). (Level of Evidence: A)
CLASS IIa
1. It is reasonable to initiate ACE inhibitors or angiotensin-receptor
blockers postoperatively and to continue them indefinitely in all
CABG patients who were not receiving them preoperatively and
are considered to be at low risk (i.e., those with a normal LVEF in
whom cardiovascular risk factors are well controlled), unless con-
traindicated (278–282). (Level of Evidence: B)
CLASS IIb
1. The safety of the preoperative administration of ACE inhibitors or
angiotensin-receptor blockers in patients on chronic therapy is
uncertain (283–288). (Level of Evidence: B)
. The safety of initiating ACE inhibitors or angiotensin-receptor blockers
before hospital discharge is not well established (278,280,282,289).
(Level of Evidence: B)
4.7. Smoking Cessation
CLASS I
1. All smokers should receive in-hospital educational counseling and
be offered smoking cessation therapy during CABG hospitalization
(291–293,293a). (Level of Evidence: A)
CLASS IIb
1. The effectiveness of pharmacological therapy for smoking cessa-
tion offered to patients before hospital discharge is uncertain. (Level
of Evidence: C)
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Psychosocial Considerations
CLASS IIa
1. Cognitive behavior therapy or collaborative care for patients with
clinical depression after CABG can be beneficial to reduce objective
measures of depression (294–298). (Level of Evidence: B)
4.9. Cardiac Rehabilitation
CLASS I
1. Cardiac rehabilitation is recommended for all eligible patients after
CABG (299–301,301a–301d). (Level of Evidence: A)
4.10. Perioperative Monitoring
4.10.1. Electrocardiographic Monitoring
CLASS I
1. Continuous monitoring of the electrocardiogram for arrhythmias
should be performed for at least 48 hours in all patients after CABG
(265,302,303). (Level of Evidence: B)
CLASS IIa
1. Continuous ST-segment monitoring for detection of ischemia is
reasonable in the intraoperative period for patients undergoing
CABG (56,304–306). (Level of Evidence: B)
CLASS IIb
1. Continuous ST-segment monitoring for detection of ischemia may
be considered in the early postoperative period after CABG
(272,302,307–310). (Level of Evidence: B)
4.10.2. Pulmonary Artery Catheterization
CLASS I
1. Placement of a pulmonary artery catheter is indicated, preferably
before the induction of anesthesia or surgical incision, in patients in
cardiogenic shock undergoing CABG. (Level of Evidence: C)
CLASS IIa
1. Placement of a pulmonary artery catheter can be useful in the
intraoperative or early postoperative period in patients with acute
hemodynamic instability (311–316). (Level of Evidence: B)
CLASS IIb
1. Placement of a pulmonary artery catheter may be reasonable in
clinically stable patients undergoing CABG after consideration of
baseline patient risk, the planned surgical procedure, and the
practice setting (311–316). (Level of Evidence: B)
4.10.3. Central Nervous System Monitoring
CLASS IIb
1. The effectiveness of intraoperative monitoring of the processed
electroencephalogram to reduce the possibility of adverse recall of
clinical events or for detection of cerebral hypoperfusion in CABG
patients is uncertain (449–451). (Level of Evidence: B)
2. The effectiveness of routine use of intraoperative or early postoper-
ative monitoring of cerebral oxygen saturation via near-infrared
spectroscopy to detect cerebral hypoperfusion in patients undergo-ing CABG is uncertain (317–319). (Level of Evidence: B)5. CABG-Associated Morbidity and
Mortality: Occurrence and
Prevention: Recommendations
5.1. Public Reporting of Cardiac Surgery Outcomes
CLASS I
1. Public reporting of cardiac surgery outcomes should use risk-
adjusted results based on clinical data (320–327). (Level of
Evidence: B)
5.1.1. Use of Outcomes or Volume as
CABG Quality Measures
CLASS I
1. All cardiac surgery programs should participate in a state, regional,
or national clinical data registry and should receive periodic reports
of their risk-adjusted outcomes. (Level of Evidence: C)
CLASS IIa
1. When credible risk-adjusted outcomes data are not available, vol-
ume can be useful as a structural metric of CABG quality (328–342).
(Level of Evidence: B)
CLASS IIb
1. Affiliation with a high-volume tertiary center might be considered by
cardiac surgery programs that perform fewer than 125 CABG pro-
cedures annually. (Level of Evidence: C)
5.2. Use of Epiaortic Ultrasound Imaging to Reduce
Stroke Rates
CLASS IIa
1. Routine epiaortic ultrasound scanning is reasonable to evaluate the
presence, location, and severity of plaque in the ascending aorta to
reduce the incidence of atheroembolic complications (343–345).
(Level of Evidence: B)
5.3. The Role of Preoperative Carotid Artery
Noninvasive Screening in CABG Patients
CLASS I
1. A multidisciplinary team approach (consisting of a cardiologist,
cardiac surgeon, vascular surgeon, and neurologist) is recom-
mended for patients with clinically significant carotid artery disease
for whom CABG is planned. (Level of Evidence: C)
CLASS IIa
1. Carotid artery duplex scanning is reasonable in selected patients
who are considered to have high-risk features (i.e., age 65 years,
left main coronary stenosis, peripheral artery disease, history of
cerebrovascular disease [transient ischemic attack, stroke, etc.],
hypertension, smoking, and diabetes mellitus) (346,347). (Level of
Evidence: C)
2. In the CABG patient with a previous transient ischemic attack or
stroke and a significant (50% to 99%) carotid artery stenosis, it is
reasonable to consider carotid revascularization in conjunction with
CABG. In such an individual, the sequence and timing (simultaneous
or staged) of carotid intervention and CABG should be determined
by the patient’s relative magnitudes of cerebral and myocardial
dysfunction. (Level of Evidence: C)
CLASS IIb
1. In the patient scheduled to undergo CABG who has no history oftransient ischemic attack or stroke, carotid revascularization may
34
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carotid stenoses or a unilateral severe carotid stenosis with a
contralateral occlusion. (Level of Evidence: C)
5.4. Mediastinitis/Perioperative Infection
CLASS I
1. Preoperative antibiotics should be administered to all patients to
reduce the risk of postoperative infection (348–353). (Level of
Evidence: A)
2. A first- or second-generation cephalosporin is recommended for
prophylaxis in patients without methicillin-resistant Staphylococcus
aureus colonization (353–361). (Level of Evidence: A)
. Vancomycin alone or in combination with other antibiotics to
achieve broader coverage is recommended for prophylaxis in pa-
tients with proven or suspected methicillin-resistant S. aureus colo-
nization (356,362–364). (Level of Evidence: B)
. A deep sternal wound infection should be treated with aggressive
surgical debridement in the absence of complicating circum-
stances. Primary or secondary closure with muscle or omental flap
is recommended (365–367). Vacuum therapy in conjunction with
early and aggressive debridement is an effective adjunctive therapy
(368–377). (Level of Evidence: B)
. Use of a continuous intravenous insulin protocol to achieve and
maintain an early postoperative blood glucose concentration less
than or equal to 180 mg/dL while avoiding hypoglycemia is indi-
cated to reduce the risk of deep sternal wound infection
(256,259,378–381). (Level of Evidence: B)
CLASS IIa
1. When blood transfusions are needed, leukocyte-filtered blood can
be useful to reduce the rate of overall perioperative infection and
in-hospital death (382–385). (Level of Evidence: B)
. The use of intranasal mupirocin is reasonable in nasal carriers of S.
aureus (386,387). (Level of Evidence: A)
3. The routine use of intranasal mupirocin is reasonable in patients
who are not carriers of S. aureus, unless an allergy exists. (Level of
Evidence: C)
CLASS IIb
1. The use of bilateral internal mammary arteries in patients with
diabetes mellitus is associated with an increased risk of deep
sternal wound infection, but it may be reasonable when the overall
benefit to the patient outweighs this increased risk. (Level of
Evidence: C)
5.5. Renal Dysfunction
CLASS IIb
1. In patients with preoperative renal dysfunction (creatinine clear-
ance 60 mL/min), off-pump CABG may be reasonable to reduce
the risk of acute kidney injury (388–392). (Level of Evidence: B)
. In patients with preexisting renal dysfunction undergoing on-pump
CABG, maintenance of a perioperative hematocrit greater than 19%
and mean arterial pressure greater than 60 mm Hg may be reason-
able. (Level of Evidence: C)
. In patients with preexisting renal dysfunction, a delay of surgery
after coronary angiography may be reasonable until the effect of
radiographic contrast material on renal function is assessed (393–
395). (Level of Evidence: B)
. The effectiveness of pharmacological agents to provide renal pro-
tection during cardiac surgery is uncertain (396–418). (Level of
Evidence: B)5.6. Perioperative Myocardial Dysfunction
CLASS IIa
1. In the absence of severe, symptomatic aorto-iliac occlusive disease
or peripheral artery disease, the insertion of an intra-aortic balloon
is reasonable to reduce mortality rate in CABG patients who are
considered to be at high risk (e.g., those who are undergoing
reoperation or have LVEF30% or left main CAD) (419–424). (Level
of Evidence: B)
2. Measurement of biomarkers of myonecrosis (e.g., creatine kinase-
MB, troponin) is reasonable in the first 24 hours after CABG (425).
(Level of Evidence: B)
5.6.1. Transfusion
CLASS I
1. Aggressive attempts at blood conservation are indicated to limit he-
modilutional anemia and the need for intraoperative and perioperative
allogeneic red blood cell transfusion in CABG patients (426–429).
(Level of Evidence: B)
5.7. Perioperative Dysrhythmias
CLASS I
1. Beta blockers should be administered for at least 24 hours before
CABG to all patients without contraindications to reduce the incidence
or clinical sequelae of postoperative AF (263–267,267a–267c). (Level
of Evidence: B)
2. Beta blockers should be reinstituted as soon as possible after CABG in
all patients without contraindications to reduce the incidence or clinical
sequelae of AF (263–267,267a–267c). (Level of Evidence: B)
CLASS IIa
1. Preoperative administration of amiodarone to reduce the incidence
of postoperative AF is reasonable for patients at high risk for
postoperative AF who have contraindications to beta blockers
(430). (Level of Evidence: B)
2. Digoxin and nondihydropyridine calcium channel blockers can be
useful to control the ventricular rate in the setting of AF but are not
indicated for prophylaxis (265). (Level of Evidence: B)
5.8. Perioperative Bleeding/Transfusion
CLASS I
1. Lysine analogues are useful intraoperatively and postoperatively in
patients undergoing on-pump CABG to reduce perioperative blood
loss and transfusion requirements (431–438). (Level of Evidence: A)
2. A multimodal approach with transfusion algorithms, point-of-
care testing, and a focused blood conservation strategy should
be used to limit the number of transfusions (439–444). (Level of
Evidence: A)
3. In patients taking thienopyridines (clopidogrel or prasugrel) or ti-
cagrelor in whom elective CABG is planned, clopidogrel and ticagre-
lor should be withheld for at least 5 days (224,225,227,228,445–
451) (Level of Evidence: B) and prasugrel for at least 7 days (452)
(Level of Evidence: C) before surgery.
4. It is recommended that surgery be delayed after the administration
of streptokinase, urokinase, and tissue-type plasminogen activators
until hemostatic capacity is restored, if possible. The timing of
recommended delay should be guided by the pharmacodynamic
half-life of the involved agent. (Level of Evidence: C)
5. Tirofiban or eptifibatide should be discontinued at least 2 to 4 hours
before CABG and abciximab at least 12 hours before CABG (230–
232,436,437,453–457). (Level of Evidence: B)
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1. It is reasonable to consider off-pump CABG to reduce perioperative
bleeding and allogeneic blood transfusion (458–464). (Level of
Evidence: A)
6. Specific Patient Subsets:
Recommendations
6.1. Anomalous Coronary Arteries
CLASS I
1. Coronary revascularization should be performed in patients with:
a. A left main coronary artery that arises anomalously and then
courses between the aorta and pulmonary artery (465–467).
(Level of Evidence: B)
b. A right coronary artery that arises anomalously and then courses
between the aorta and pulmonary artery with evidence of myo-
cardial ischemia (465–468). (Level of Evidence: B)
CLASS IIb
1. Coronary revascularization may be reasonable in patients with a
LAD coronary artery that arises anomalously and then courses
between the aorta and pulmonary artery. (Level of Evidence: C)
6.2. Patients With Chronic Obstructive
Pulmonary Disease/Respiratory Insufficiency
CLASS IIa
1. Preoperative intensive inspiratory muscle training is reasonable to
reduce the incidence of pulmonary complications in patients at high
risk for respiratory complications after CABG (469). (Level of Evi-
dence: B)
CLASS IIb
1. After CABG, noninvasive positive pressure ventilation may be rea-
sonable to improve pulmonary mechanics and to reduce the need
for reintubation (470,471). (Level of Evidence: B)
. High thoracic epidural analgesia may be considered to improve lung
function after CABG (472,473). (Level of Evidence: B)
6.3. Patients With End-Stage Renal Disease
on Dialysis
CLASS IIb
1. CABG to improve survival rate may be reasonable in patients with
end-stage renal disease undergoing CABG for left main coronary
artery stenosis of greater than or equal to 50% (474). (Level of
Evidence: C)
2. CABG to improve survival rate or to relieve angina despite GDMT
may be reasonable for patients with end-stage renal disease with
significant stenoses (70%) in 3 major vessels or in the proximal
LAD artery plus 1 other major vessel, regardless of LV systolic
function (475). (Level of Evidence: B)
CLASS III: HARM
1. CABG should not be performed in patients with end-stage renal
disease whose life expectancy is limited by noncardiac issues.
(Level of Evidence: C)
6.4. Patients With Concomitant Valvular Disease
CLASS I
1. Patients undergoing CABG who have at least moderate aortic stenosis
should have concomitant aortic valve replacement (476–479). (Level
of Evidence: B). Patients undergoing CABG who have severe ischemic mitral valve
regurgitation not likely to resolve with revascularization should have
concomitant mitral valve repair or replacement at the time of CABG
(480–485). (Level of Evidence: B)
CLASS IIa
1. In patients undergoing CABG who have moderate ischemic mitral
valve regurgitation not likely to resolve with revascularization, con-
comitant mitral valve repair or replacement at the time of CABG is
reasonable (480–485). (Level of Evidence: B)
CLASS IIb
1. Patients undergoing CABG who have mild aortic stenosis may be
considered for concomitant aortic valve replacement when evi-
dence (e.g., moderate–severe leaflet calcification) suggests that
progression of the aortic stenosis may be rapid and the risk of the
combined procedure is acceptable. (Level of Evidence: C)
6.5. Patients With Previous Cardiac Surgery
CLASS IIa
1. In patients with a patent LIMA to the LAD artery and ischemia in the
distribution of the right or left circumflex coronary arteries, it is
reasonable to recommend reoperative CABG to treat angina if
GDMT has failed and the coronary stenoses are not amenable to PCI
(186,486). (Level of Evidence: B)
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